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The aims of this study were to determine the prevalence of anti-PLAC1 antibodies in normal pregnant women and in women with
infertility or recurrent pregnancy loss (RPL). Secondary outcomes were the development of complications associated with antiPLAC1 seropositivity and the rate of seroconversion during pregnancy. Sera from 103 healthy pregnant women and 45 women
with unexplained infertility or RPL were analyzed by ELISA. The prevalence of anti-PLAC1 antibodies was 2% in healthy pregnant
women and 4.5% in women with unexplained infertility or RPL (P = 0.355). There was no detectable association of seropositivity
with increased risk of pregnancy complications. Finally, 2% of women seroconverted during pregnancy. The prevalence of antiPLAC1 antibodies in women with unexplained infertility or RPL is not significantly higher than the prevalence in normal pregnant
women. However, the sample size in this study was too small. The exposure to the PLAC1 antigen during pregnancy can lead to
the spontaneous development of antibodies.

1. Introduction
PLAC1 (PLACenta-specific 1) is an X-linked gene that
encodes a protein localized to membranous compartments
of cells of trophoblast lineage. It maps to a locus on the Xchromosome known to be important for placental development [1, 2]. Although its expression is highly restricted to the
trophoblast [2, 3], its exact function in the placenta remains
unclear. A significant role for PLAC1 in normal placental
development was suggested by aberrant placentation, fetal
growth retardation, and neonatal death in mice that have
large deletions of the X-chromosome in the region where
PLAC1 maps [4, 5]. Additionally, clinical studies in pregnant
women reported that markedly decreased concentration of
PLAC1 mRNA in maternal plasma was associated with
vaginal bleeding during the first twenty weeks of pregnancy
[6].
While PLAC1 expression is restricted to the placenta in
normal tissues [1–3], it is also ectopically expressed in a variety of human cancers, including breast, lung, gastric, colon,

and ovarian [7–11]. Evidence from in vitro studies using the
MCF-7 breast cancer cell line suggests that PLAC1 promotes
cell proliferation and motility, processes essential to tumor
survival [12]. Independent studies from Tchabo et al., Dong
et al., and Silva et al. reported the presence of anti-PLAC1
autoantibodies in some cancer patients [9–11]. Additionally,
Liu et al. reported that the PLAC1 protein also elicits a
CD8-mediated cytotoxic response that appeared to improve
survival in a small cohort of colorectal patients [13]. Collectively, these studies suggested that expression of the PLAC1
antigen can elicit a spontaneous antibody/immunologic
response capable of altering tumor cell biology. In the
study by Silva et al., anti-PLAC1 autoantibodies were also
detected in a small percentage of healthy control patients.
Interestingly, the observed immunoreactivity was restricted
to females, suggesting that they were likely exposed to the
PLAC1 antigen during a prior pregnancy [11]. The ability of
these antibodies to interact with trophoblast-derived PLAC1
and alter placental function under normal physiological
circumstances is unknown. We therefore hypothesized that
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the presence of anti-PLAC1 autoantibodies would adversely
aﬀect PLAC1 function during the early development of
the placenta, resulting in increased reproductive loss or
pregnancy complications.
In order to begin examining this question, our initial
objectives were to define the prevalence of anti-PLAC1
seropositivity in a population of healthy pregnant women
and compare it to the prevalence of anti-PLAC1 seropositivity in women with a history of unexplained infertility or
RPL.

2. Materials and Methods
This study was approved by the Institutional Review Board
of the University of South Florida. Informed consent was
obtained from each patient.
2.1. Subjects. 103 primigravid or multigravid women were
screened at their first prenatal visit at the obstetric clinic at
the South Tampa Center, University of South Florida College
of Medicine. Blood was obtained if the first visit occurred
prior to 20 weeks’ gestation and the patients were undergoing
a blood draw as part as their routine prenatal evaluation.
Subsequent samples were also obtained during pregnancy as
part of routine clinical testing, up to five times.
Blood samples were also obtained from 45 patients
with either unexplained infertility or recurrent pregnancy
loss from the infertility clinic at the South Tampa Center,
University of South Florida College of Medicine. Unexplained infertility patients were infertile for at least a
year and had undergone a standard clinical evaluation
including semen analysis, prolactin levels, thyroid stimulating hormone (TSH) levels, and tubal patency. Patients
with recurrent pregnancy loss (RPL) had suﬀered at least
two unexplained previous miscarriages before 20 weeks’
gestation. All presumptive etiological factors (anatomic, hormonal, chromosomal, infections, and thrombophilic) had
been ruled out. Exclusion criteria for both groups included
the presence of significant underlying disease, that is, cardiac
disease, renal disease, chronic hypertension, chromosomal
abnormalities, and cancer.
The blood sample was obtained by peripheral venipuncture and placed into a yellow-top BD vacutainer tube for later
determination of the presence of anti-PLAC1 autoantibodies
in serum. Serum was separated by centrifugation after clot
formation and stored at −20◦ C until analysis.
2.2. ELISA Assay for Determination of Serum Anti-PLAC1
Autoantibodies. His-tagged, rPLAC1 was produced and
purified using a baculovirus expression system as previously
described [2]. The presence of anti-PLAC1 autoantibodies in
serum was measured by an ELISA assay using recombinant
PLAC1 (rPLAC1) as coating antigen. Briefly, microtiter
medium binding 96-well plates (CostarR 3591, NY 14831)
were coated with PLAC1 protein by adding 150 uL of a
solution of rPLAC1 (1 ug/mL) to each well and incubated
overnight at 4◦ C. Wells were washed with a solution of
PBS containing 0.1% of TWEEN 20 (Fisher Scientific, NJ
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07410) three times and then blocked by incubation for 1.5
hours with the Blocking Solution (CANDOR Bioscience
GmBH, Germany). After decanting the blocking buﬀer, a
150 uL aliquot of patient serum (diluted 1 : 100 in PBS)
was added to each well. Normal human serum diluted to
1 : 100 (Jackson ImmunoResearch, PA 19390) was used as a
negative control. Recombinant rabbit anti-PLAC1 antibody,
diluted to 1 : 5,000, was initially used as a positive control
until a positive patient sample was identified. The plates
were incubated for 1.5 h at room temperature. The wells
were then washed three times with PBS-TWEEN 20 at
0.1% and incubated with a peroxidase-linked goat antihuman IgG (Jackson ImmunoResearch, PA 19390) diluted
1 : 20,000 in blocking solution or with a peroxidase-linked
goat anti-rabbit IgG (Millipore, MA 01821) diluted 1 : 15,000
in PBS for 1 hour. After washing, 100 uL of TMB substrate
(Thermo Scientific, IL 61101) were added to each well as
colorimetric substrate. The reaction was terminated with
100 uL of Stop Solution (Thermo Scientific, IL 61101). The
absorbance was read at 450 nm on an automatic microELISA plate reader. All samples were run in triplicate.
Normal ranges were calculated using serum values obtained
from healthy pregnant women. The cut-oﬀ representing a
positive antibody response was defined as the mean optical
density (OD) + 4SD of the healthy pregnant women after
discarding all OD above the 95th percentile. The specificity
of serum samples determined to be positive for anti-PLAC1
autoantibodies was tested by using insulin, transforming
growth factor-α, and endothelin as coating antigens.
2.3. Statistical Analysis. All patient data were stored on a
secure server. Statistical analysis was performed using SPSS
17.0 program (SPSS Inc., Chicago, IL, USA). We determined
our sample size based on a previous study, which had shown
a prevalence of 5% in a small cohort (n = 78) healthy female
volunteers [11]. Based on the assumption that the prevalence
of the antibody in the low-risk population was 5% and that
the prevalence would be 25% in the high-risk population,
120 subjects (60/group) were needed in order to have at least
80% power at 0.05 significant level with one sided test.
Quantitative data were described as mean ± SD and the
diﬀerences between values were determined by Student’s ttest when normally distributed. If the distribution was non
parametric, diﬀerences were analyzed using Mann-Whitney
comparisons by ranks and the data described as median
and range. Frequency data were compared using χ 2 or
Fisher’s exact test. Statistical tests were considered significant
whenever P-value was <0.05.

3. Results
A cohort of normal pregnant women and women with
histories of infertility/RPL agreed to participate in the
study. Table 1 summarizes the demographic and clinical
characteristics of the patients included in the study. Women
with histories of infertility/RPL were significantly older than
the healthy pregnant women; 22 (48.9%) of them had a
history of infertility and 23 (51.1%) had a diagnosis of RPL.
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Table 1: Demographics of the patients included in the study.

Women with unexplained infertility or RPL (n = 45)
Age at inclusion in study, mean (SD)
35 (±4.46)
28 (±8)
Body mass index (kg/m2 )a , mean (SD)
Ethnicity, n (%)
Caucasian
35 (78)
African-American
1 (2.5)
Hispanic
6 (13.5)
Asian
2 (4.4)
Missing
1 (2.2)
Smokers (n, %)
11 (24)
Gravida (median, range)
1.5 (0–10)
Abortions (median, range)
1 (0–6)
a

Healthy pregnant women (n = 103)
30.6 (±5.5)
27 (±7)

P
0.00
0.43

73 (71)
11 (12)
13 (13)
1 (1)
5 (5)
15 (14.5)
2 (0–6)
0 (0–2)

0.15
0.18
0.00

Prepregnancy weight was used to determine BMI in healthy pregnant women.
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Figure 1: Mean OD readings of anti PLAC1 antibodies in patients
with history of infertility/RPL versus healthy pregnant women. The
dotted line shows the mean OD + 4SD of healthy pregnant women.
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Figure 2: Antibody titer of positive serum samples.

Anti-PLAC1 autoantibodies were detected in 2% (n = 2
of 103) of healthy pregnant women. By contrast, a prevalence
of 4.5% (n = 2 of 45) was obtained for the cohort of women
with a history of infertility/RPL (Figure 1). There was no statistical diﬀerence in anti-PLAC1 seropositivity between these
groups (P = 0.355). In the 4 positive sera for anti-PLAC1
antibodies, the titers ranged from 1 : 50 to 1 : 500 (Figure 2).
Based on the current data, a sample size of 1141 patients per

group would be required to demonstrate a significant twofold increase in the prevalence of seropositivity in women
with unexplained infertility/RPL. Approximately 39% (41
of 104) of healthy pregnant women had subsequent blood
samples drawn during their pregnancy. Of these, 1 patient
exhibited seroconversion on a second sample tested (data not
shown).
Of the 5 women positive for anti-PLAC1 autoantibodies,
4 were Caucasian and 1 was African-American. Of the four
cases that were positive at the initial sampling (2 normal
pregnant women, 2 infertility/RPL), three had histories of
prior pregnancies and/or miscarriages and one was a primigravida. Interestingly, the primigravid patient had a history
of a loop electro-excision procedure (LEEP procedure)
performed secondary to an abnormal papanicolaou smear
raising the intriguing possibility that PLAC1 may have been
ectopically expressed by dysplastic cervical epithelial cells.
The patient that exhibited seroconversion on her second
serum sample had two previous pregnancies, one of them
associated with the intrauterine fetal demise of twins.
At the time of the submission of this manuscript, 2 of the
3 anti-PLAC1 seropositive patients in the healthy cohort of
pregnant women had delivered a term infant by spontaneous
vaginal delivery. The only complication reported during
the pregnancy for one of them was gestational diabetes. In
the group of women with a history of infertility/RPL, one
of the seropositive patients became pregnant and received
her prenatal care outside of the USF clinics. Complications
during the pregnancy and/or delivery for women negative
for anti-PLAC1 antibodies are described in Table 2. No
detectable signal indicating an increased risk for adverse
events emerged from these data.

4. Discussion
Reproductive failure including recurrent spontaneous abortion and infertility can result from multiple causes: chromosomal abnormalities, infection, uterine abnormalities,
hormonal factors, and systemic disease. After evaluation
for these causes, about 10% of all cases remain unexplained [14–17]. Recently, the search for etiologic factors
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Table 2: Pregnancy outcomes of the women included in the study.

Preeclampsia
Maternal PIH
Preterm labor
Fetal distress
Chorioamnionitis
Gestational diabetes
IUGR
Clotting abnormalities

Women negative for
antiPLAC1
(n = 86)∗
4 (5%)
10 (12%)
1 (1.2%)
3 (3.5%)
5 (6%)
7 (8%)
0
2 (2.4)

Women positive
for antiPLAC1
(n = 5)
0
0
0
0
0
1
0
0

∗

Outcomes missing in 17 patients due to loss of follow-up or pending
deliveries.

contributing to unexplained infertility and recurrent abortions has included the possible role of immune-mediated
processes. Autoantibodies that appear to be associated
with reproductive failure include anti-phospholipid (anticardiolipin, lupus anticoagulant, anti-2 glycoprotein1), antilaminin, antibodies against nuclear antigens (ANAs), antiprothrombin antibodies (aPTs), antisperm antibodies, and
antisacchromyces cerevisiae antibodies among others. However, these antibodies are not pathognomonic of pregnancy
failure. Their role remains controversial due to diﬀering
prevalence, lack of controls, and small sample sizes among
studies [18–21].
The initial observation by Silva et al. [11] that autoantibodies directed against PLAC1 expressed by human cancer
also circulated in a small number of normal women without
cancer raised some intriguing questions. First, it suggested
that these women may have been exposed during a previous
pregnancy since no antibodies were detected in the men who
were part of the same control group. Secondly, and more
important, it raised the question of whether or not antiPLAC1 autoantibodies could potentially interact with PLAC1
in the trophoblast to alter placental function and adversely
aﬀect pregnancy outcome. The highly restricted expression
of PLAC1 by the placenta and its potential importance
for placental development make it an attractive target for
autoantibodies that may have functional significance in
reproduction.
Since this study began, a role for Plac1 at the fetalmaternal interface has been confirmed by our laboratory
using a mouse mutant model [22, manuscript in preparation]. Deletions of the Plac1 gene resulted in placentomegaly
and intrauterine growth retardation suggesting diminished
functional capacity of the placenta. Although the Plac1
mutants were capable of survival, they exhibited decreased
viability prior to weaning. The basis for this diminished
placental function (and viability) has not been determined
but may be related to diminished implantation, alterations
in genes important for nutrient transport, or perhaps
secondary to physical constraints imposed on the labyrinth
(where nutrient transport occurs) by contiguous areas of
overgrowth. Plac1 expression has been demonstrated in all

of the trophoblast lineages in the mouse including the
labyrinth and in trophoblast giant cells that possess invasive
characteristics and are important during the early stages
placentation. Using a breast cancer cell line, Koslowski
et al. [12] demonstrated the importance of PLAC1 in
modulating cell proliferation and invasion. Although there is
no direct experimental evidence, the presence of anti-PLAC1
antibodies could potentially alter placentation during the
initial phases of trophoblast invasion of maternal decidua,
myometrium, and blood vessels. Given its expression in the
labyrinth of the mouse placenta and the analogous chorionic
villus syncytiotrophoblast of the human placenta, Plac1 may
also play a more direct role in nutrient and gas exchange
throughout gestation.
In the current study, we detected anti-PLAC1 antibodies
in 2% of healthy pregnant women early in pregnancy. This
was lower than the prevalence reported by Silva et al. for
their group of control, noncancer patients [11]. This could
be explained by the fact that our control population consisted
of a stringently selected group of pregnant women while the
characteristics of the control population in Silva et al. study
were selected solely on the presence or absence of cancer.
Approximately 4.5% of women with infertility/RPL had
detectable anti-PLAC1 autoantibodies. This suggests a trend
toward a twofold increase in the prevalence of antibodies in
women with documented reproductive problems compared
to normal pregnant women. However, the sample size used
for this report was designed to test for a fivefold diﬀerence
in prevalence and therefore too small to adequately test the
significance of the twofold diﬀerence observed here. Given
the relatively small sample size of our study, a post hoc power
calculation was performed that showed that our study only
had a power of 9% to show a twofold diﬀerence in the
prevalence rate between the groups.
In summary, we demonstrated that the prevalence of
anti-PLAC1 antibodies is approximately 2% in healthy
pregnant women, early in gestation. We also demonstrated,
for the first time, the spontaneous development of antiPLAC1 antibodies during pregnancy. Finally, although there
is a trend towards an increased prevalence of anti-PLAC1
antibodies in women with infertility/RPL, more patients
need to be studied to determine the significance of this
observation. In view of the observation that Plac1-null
mice are capable of survival [22], it is not surprising
that the presence of anti-PLAC1 antibodies did not appear
to be associated with dramatic adverse outcomes in our
relatively small patient sample. The functional impact of
these antibodies may involve specific pathways that are
important for optimal placental function but not absolutely
required for pregnancy maintenance. Future studies will
be directed towards characterizing the PLAC1-antibody
interaction. Specifically, the antigenic epitopes eliciting the
antibody response will be determined for each patient to
determine if they are directed against the same part of
the protein and to determine if they interact with epitopes
involved in specific PLAC1-protein interactions relevant
to its function at the cellular level. This will permit the
interaction of anti-PLAC1 antibodies with specific signaling
pathways to be examined.
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